Overview
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist structured with distinct chemical modifications for structural stability and albumin binding. By incorporating a non-proteinogenic amino acid substitution and a specific fatty acid side chain, Semaglutide exhibits resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). This extended systemic half-life allows researchers to evaluate sustained GLP-1 receptor activation and its profound downstream effects on glycemic control, appetite regulation, and cardiovascular biomarkers.
Disclaimer: This product is for research purposes only. It is not intended for direct human consumption.






Reviews
There are no reviews yet.